{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Selexipag",
    "query": {
      "intervention": "Selexipag"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 15,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Selexipag&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T12:44:06.704Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03078907",
      "title": "Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Selexipag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 108,
      "start_date": "2017-11-08",
      "completion_date": "2020-02-10",
      "has_results": true,
      "last_update_posted_date": "2025-03-30",
      "last_synced_at": "2026-09-02T12:44:06.704Z",
      "location_count": 15,
      "location_summary": "Torrance, California • Atlanta, Georgia • Louisville, Kentucky + 11 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03078907"
    },
    {
      "nct_id": "NCT01389206",
      "title": "Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 797,
      "start_date": "2011-06-01",
      "completion_date": "2018-04-10",
      "has_results": false,
      "last_update_posted_date": "2018-08-15",
      "last_synced_at": "2026-09-02T12:44:06.704Z",
      "location_count": 75,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01389206"
    },
    {
      "nct_id": "NCT03492177",
      "title": "A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "selexipag (Uptravi)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 63,
      "start_date": "2018-07-23",
      "completion_date": "2026-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-09-02T12:44:06.704Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Iowa City, Iowa • Seattle, Washington",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03492177"
    },
    {
      "nct_id": "NCT04435782",
      "title": "A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "JNJ-67896049",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 9,
      "start_date": "2021-07-07",
      "completion_date": "2023-07-28",
      "has_results": true,
      "last_update_posted_date": "2025-03-30",
      "last_synced_at": "2026-09-02T12:44:06.704Z",
      "location_count": 3,
      "location_summary": "La Jolla, California • Anderson, South Carolina • Dallas, Texas",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Anderson",
          "state": "South Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04435782"
    },
    {
      "nct_id": "NCT01106014",
      "title": "Selexipag (ACT-293987) in Pulmonary Arterial Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Selexipag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1156,
      "start_date": "2009-12-01",
      "completion_date": "2014-10-01",
      "has_results": true,
      "last_update_posted_date": "2025-10-27",
      "last_synced_at": "2026-09-02T12:44:06.704Z",
      "location_count": 43,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • La Jolla, California + 32 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01106014"
    },
    {
      "nct_id": "NCT04175600",
      "title": "A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertension, Pulmonary"
      ],
      "interventions": [
        {
          "name": "Selexipag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care (SOC): Endothelin receptor antagonist",
          "type": "DRUG"
        },
        {
          "name": "SOC: Phosphodiesterase type 5 (PDE-5) inhibitor",
          "type": "DRUG"
        },
        {
          "name": "SOC: Soluble guanylate cyclase stimulator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 138,
      "start_date": "2020-01-16",
      "completion_date": "2027-10-01",
      "has_results": true,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-09-02T12:44:06.704Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04175600"
    },
    {
      "nct_id": "NCT02558231",
      "title": "The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Macitentan",
          "type": "DRUG"
        },
        {
          "name": "Tadalafil",
          "type": "DRUG"
        },
        {
          "name": "Selexipag",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 247,
      "start_date": "2016-05-01",
      "completion_date": "2020-04-20",
      "has_results": true,
      "last_update_posted_date": "2025-03-30",
      "last_synced_at": "2026-09-02T12:44:06.704Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Weston",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02558231"
    },
    {
      "nct_id": "NCT07759804",
      "title": "A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension (PAH)"
      ],
      "interventions": [
        {
          "name": "LIQ861 (treprostinil) inhalation powder",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Liquidia Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-09",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-09-02T12:44:06.704Z",
      "location_count": 1,
      "location_summary": "Columbus, Georgia",
      "locations": [
        {
          "city": "Columbus",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07759804"
    },
    {
      "nct_id": "NCT03942211",
      "title": "A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoidosis-associated Pulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "Selexipag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2021-02-26",
      "completion_date": "2023-04-19",
      "has_results": true,
      "last_update_posted_date": "2024-05-08",
      "last_synced_at": "2026-09-02T12:44:06.704Z",
      "location_count": 8,
      "location_summary": "Indianapolis, Indiana • New Orleans, Louisiana • New York, New York + 5 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03942211"
    },
    {
      "nct_id": "NCT02471183",
      "title": "Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Selexipag",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 34,
      "start_date": "2015-10-12",
      "completion_date": "2016-12-05",
      "has_results": true,
      "last_update_posted_date": "2018-01-23",
      "last_synced_at": "2026-09-02T12:44:06.704Z",
      "location_count": 15,
      "location_summary": "La Jolla, California • San Francisco, California • Torrance, California + 11 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Austell",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02471183"
    }
  ]
}